Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection
Author(s) -
Patrick D. Lyden,
Sara Weymer,
Christopher S. Coffey,
Merit Cudkowicz,
Samantha Berg,
Sarah Friedlander O'Brien,
Marc Fisher,
E. Clarke Haley,
Pooja Khatri,
Jeffrey L. Saver,
Steven R. Levine,
Howard Levy,
Marilyn M. Rymer,
Lawrence R. Wechsler,
Ashutosh P. Jadhav,
Elizabeth McNeil,
Salina P. Waddy,
Kent E. Pryor
Publication year - 2016
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.116.013881
Subject(s) - medicine , clinical trial , stroke (engine) , context (archaeology) , odds ratio , adverse effect , confidence interval , intensive care medicine , physical therapy , mechanical engineering , paleontology , engineering , biology
The advent of intra-arterial neurothrombectomy (IAT) for acute ischemic stroke opens a potentially transformative opportunity to improve neuroprotection studies. Combining a putative neuroprotectant with recanalization could produce more powerful trials but could introduce heterogeneity and adverse event possibilities. We sought to demonstrate feasibility of IAT in neuroprotectant trials by defining IAT selection criteria for an ongoing neuroprotectant clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom